FDA approves Eicos’s Aurlumyn for severe frostbite treatment

15 Feb 2024
www.pharmaceutical-technology.com
Drug ApprovalOrphan DrugBreakthrough TherapyClinical ResultPriority Review
FDA approves Eicos’s Aurlumyn for severe frostbite treatment
Preview
Source: Pharmaceutical Technology
Aurlumyn injection is a new treatment option for adults with severe frostbite. Credit: movchanzemtsova / Shutterstock.com.
The US Food and Drug Administration (FDA) has approved Eicos Sciences’s Aurlumyn (iloprost) injection, a new treatment for adults with severe frostbite to lower the risk of amputation of fingers or toes.
Aurlumyn contains iloprost, a vasodilator that opens blood vessels and stops blood clotting, as its active ingredient.
The efficacy of iloprost in treating severe frostbite was established through an open-label controlled trial in 47 adult subjects.
Participants were randomised into three groups, with group one receiving iloprost intravenously for six hours daily for up to eight days along with aspirin and standard of care.
Groups two and three were administered other medications, with and without iloprost, which are not approved for frostbite treatment.
See Also:Otsuka wins FDA breakthrough therapy designation for IgAN drug
FDA approves Eicos’s Aurlumyn for severe frostbite treatment
Preview
Source: Pharmaceutical Technology
QBiotics wins FDA orphan status for rainforest-derived cancer drug
FDA approves Eicos’s Aurlumyn for severe frostbite treatment
Preview
Source: Pharmaceutical Technology
The trial’s primary efficacy measure was bone scans on day seven following the frostbite incident to predict the need for amputation.
The scans showed that none of the subjects who received iloprost alone (group one) required amputation compared to 19% in group two and 60% in group three.
This indicated a significant reduction in the presence of bone scan abnormalities in groups receiving iloprost.
Most subjects had follow-up data available to confirm whether they underwent amputation. This aligned with the bone scan findings.
Headache, flushing, heart palpitations, nausea and hypotension were common side effects linked to Aurlumyn treatment.
The treatment carries a warning for potential symptomatic hypotension.
Aurlumyn was granted priority review and orphan drug designations for this indication, highlighting its significance in addressing severe frostbite, a condition that can escalate from mild to severe, potentially leading to permanent tissue damage and the cessation of blood flow.
Iloprost originally received approval in 2004 for pulmonary arterial hypertension.
FDA Center for Drug Evaluation and Research Division of Cardiology and Nephrology director Norman Stockbridge stated: “This approval provides patients with the first-ever treatment option for severe frostbite.
“Having this new option provides physicians with a tool that will help prevent the life-changing amputation of one’s frostbitten fingers or toes.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.